文献速递小儿麻醉心胸血管麻醉

体外添加纤维蛋白原浓缩物对新生儿体外循环后血凝块结构的影响

Influence of Fibrinogen Concentrate on Neonatal Clot Structure When Administered Ex Vivo After Cardiopulmonary Bypass.
PubMed 文献 · Anesth Analg · 2023-01-24

本研究探讨体外添加纤维蛋白原浓缩物(FC)对新生儿体外循环(CPB)后血浆纤维蛋白网络结构和降解的影响。结果显示,添加0.9 mg/mL FC后纤维密度显著高于未处理CPB样本,且与体内输注冷沉淀后相当,降解速率与基线无显著差异。提示FC可能有效恢复CPB后纤维蛋白凝块结构特性。

要点

  • 体外添加0.9 mg/mL FC可显著提高新生儿CPB后血浆纤维蛋白密度。
  • 0.9 mg/mL FC组的纤维密度高于体内输注冷沉淀后的水平。
  • 添加FC未显著改变纤维排列方向及凝块降解速率。

核心结论

  • 体外以临床相关剂量0.9 mg/mL FC形成的凝块在结构和降解特性上与体内输注冷沉淀相似,提示FC可有效恢复CPB后纤维蛋白凝块结构特性。

研究设计与样本

  • 研究经机构审查委员会批准并获父母知情同意,采集接受心脏手术新生儿的血液样本并离心获得贫血小板血浆。
  • 在体外形成凝块的条件包括:基线、CPB后即刻、冷沉淀输注后、CPB后+0.5 mg/mL FC、CPB后+0.9 mg/mL FC。
  • 采用共聚焦显微镜分析纤维网络结构、纤维密度和排列,并用微流控降解试验分析凝块降解,同时量化所有血浆样本的纤维蛋白原含量。

主要发现

  • 与未处理CPB后样本相比,添加0.5或0.9 mg/mL FC显著提高中位纤维密度:CPB后=0.44(IQR 0.36-0.52),CPB后+0.5 mg/mL FC=0.69(0.56-0.77),CPB后+0.9 mg/mL FC=0.87(0.59-0.96),P值分别为.01和.006。
  • CPB后+0.9 mg/mL FC的纤维密度高于体内输注冷沉淀后:输注后=0.54(0.45-0.77) vs CPB后+0.9 mg/mL FC=0.87(0.59-0.96),P=.002。
  • CPB后样本与FC处理样本的中位纤维排列无显著差异;0.5或0.9 mg/mL FC的降解速率与基线值无统计学显著差异。
  • 控制体重后,基线至CPB后纤维蛋白原浓度差异与患者年龄显著相关(P=.033)。

临床怎么用

  • 对于CPB后新生儿,体外添加0.9 mg/mL FC可改善纤维蛋白凝块结构,效果与冷沉淀输注相当,但需体内研究验证。

局限性

  • 研究为体外实验,需未来体内给药研究验证假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bleeding is a serious complication of cardiopulmonary bypass (CPB) in neonates. Blood product transfusions are often needed to adequately restore hemostasis, but are associated with significant risks. Thus, neonates would benefit from other effective, and safe, hemostatic therapies. The use of fibrinogen concentrate (FC; RiaSTAP, CSL Behring, Marburg, Germany) is growing in popularity, but has not been adequately studied in neonates. Here, we characterize structural and degradation effects on the neonatal fibrin network when FC is added ex vivo to plasma obtained after CPB. METHODS: After approval by the institutional review board and parental consent, blood samples were collected from neonates undergoing cardiac surgery and centrifuged to yield platelet poor plasma. Clots were formed ex vivo from plasma obtained at several time points: (1) baseline, (2) immediately post-CPB, and (3) post-transfusion of cryoprecipitate. In addition, we utilized post-CPB plasma to construct the following conditions: (4) post-CPB +0.5 mg/mL FC, and (5) post-CPB +0.9 mg/mL FC. The resultant fibrin networks were imaged using confocal microscopy to analyze overall structure, fiber density, and alignment. Clots were also analyzed using a microfluidic degradation assay. Fibrinogen content was quantified for all plasma samples. RESULTS: The addition of 0.5 or 0.9 mg/mL FC to post-CPB samples significantly enhanced the median fiber density when compared to untreated post-CPB samples (post-CPB = 0.44 [interquartile range {IQR}: 0.36-0.52], post-CPB +0.5 mg/mL FC = 0.69 [0.56-0.77], post-CPB +0.9 mg/mL FC = 0.87 [0.59-0.96]; P = .01 and P = .006, respectively). The addition of 0.9 mg/mL FC to post-CPB samples resulted in a greater fiber density than that observed after the in vivo transfusion of cryoprecipitate (post-transfusion = 0.54 [0.45-0.77], post-CPB +0.9 mg/mL FC = 0.87 [0.59-0.96]; P = .002). Median fiber alignment did not differ significantly between post-CPB samples and samples treated with FC. Degradation rates were not statistically significant from baseline values with either 0.5 or 0.9 mg/mL FC. In addition, we found a significant correlation between the difference in the baseline and post-CPB fibrinogen concentration with patient age ( P = .033) after controlling for weight. CONCLUSIONS: Our results show that clots formed ex vivo with clinically relevant doses of FC (0.9 mg/mL) display similar structural and degradation characteristics compared to the in vivo transfusion of cryoprecipitate. These findings suggest that FC is effective in restoring structural fibrin clot properties after CPB. Future studies after the administration of FC in vivo are needed to validate this hypothesis.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Moiseiwitsch N, Nellenbach KA, Downey LA, et al. Influence of Fibrinogen Concentrate on Neonatal Clot Structure When Administered Ex Vivo After Cardiopulmonary Bypass. Anesth Analg. 2023. PMID: 36727748. doi:10.1213/ANE.0000000000006357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。